IDH1 and glioma: Therefore while many chromatin regulator gene mutations are not currently targetable with specific therapies, the interplay between marks, exemplified by 5mC and H3K36me3 described here or IDH1 and 5mC in glioma, suggests that multiple epigenetic regulator mutations may converge on and deregulate 5mC patterns as a common method to promote tumorigenesis.